Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-07-01 DOI:10.21873/anticanres.17649

Naphatson Phansom, Zin Zin Ei, Bhurichaya Innets, Worawat Wattanathana, Theera Rittirod, Acharawan Thongmee, Keerati Joyjamras, Pithi Chanvorachote

{"title":"Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer.","authors":"Naphatson Phansom, Zin Zin Ei, Bhurichaya Innets, Worawat Wattanathana, Theera Rittirod, Acharawan Thongmee, Keerati Joyjamras, Pithi Chanvorachote","doi":"10.21873/anticanres.17649","DOIUrl":null,"url":null,"abstract":"Background/aim: The epithelial-to-mesenchymal transition (EMT) plays an essential role in lung cancer metastasis. This study aimed to explore the EMT inhibitory effect of the new compound 6,6'-(butylazanediyl) bis (methylene) bis (2,4-dimethylphenol) (2,4-diMBD).Materials and methods: Cell survival and proliferation were determined using cell viability and colony formation assays. Migration was analyzed using a wound-healing assay. The expression of proteins and mRNAs was examined using immunofluorescence assay and real-time quantitative PCR.Results: 2,4-diMBD significantly suppressed colony formation and cell migration. In relation to its anti-migratory activity, we found that 2,4-diMBD decreased Snail, Slug, and zinc finger E-box binding homeobox (ZEB) levels at both the mRNA and protein levels, indicating EMT suppression in human lung cancer cells.Conclusion: 2,4-diMBD exerts anti-metastatic properties in lung cancer cells via EMT inhibition, and is a promising compound for the treatment of lung cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 7","pages":"2807-2815"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17649","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The epithelial-to-mesenchymal transition (EMT) plays an essential role in lung cancer metastasis. This study aimed to explore the EMT inhibitory effect of the new compound 6,6'-(butylazanediyl) bis (methylene) bis (2,4-dimethylphenol) (2,4-diMBD).

Materials and methods: Cell survival and proliferation were determined using cell viability and colony formation assays. Migration was analyzed using a wound-healing assay. The expression of proteins and mRNAs was examined using immunofluorescence assay and real-time quantitative PCR.

Results: 2,4-diMBD significantly suppressed colony formation and cell migration. In relation to its anti-migratory activity, we found that 2,4-diMBD decreased Snail, Slug, and zinc finger E-box binding homeobox (ZEB) levels at both the mRNA and protein levels, indicating EMT suppression in human lung cancer cells.

Conclusion: 2,4-diMBD exerts anti-metastatic properties in lung cancer cells via EMT inhibition, and is a promising compound for the treatment of lung cancer.

查看原文本刊更多论文

靶向肺癌上皮细胞向间质转化的苯并恶嗪类抑制剂的研究进展。

背景/目的：上皮-间质转化（epithelial-to-mesenchymal transition， EMT）在肺癌转移中起重要作用。本研究旨在探讨新化合物6,6′-（丁氮二基）双（亚甲基）双（2,4-二甲基苯酚）（2,4- dimbd）对EMT的抑制作用。材料和方法：采用细胞活力和集落形成法测定细胞存活和增殖。用伤口愈合试验分析迁移。采用免疫荧光法和实时定量PCR检测蛋白和mrna的表达。结果：2,4- dimbd显著抑制菌落形成和细胞迁移。关于其抗迁移活性，我们发现2,4- dimbd在mRNA和蛋白水平上降低了Snail， Slug和zinc finger E-box binding homeobox （ZEB）水平，表明EMT在人肺癌细胞中具有抑制作用。结论：2,4- dimbd通过抑制EMT在肺癌细胞中发挥抗转移作用，是一种有前景的治疗肺癌的化合物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.